CN106038534A - 冬凌草甲素在制备抗抑郁症药物中的用途 - Google Patents
冬凌草甲素在制备抗抑郁症药物中的用途 Download PDFInfo
- Publication number
- CN106038534A CN106038534A CN201610493245.1A CN201610493245A CN106038534A CN 106038534 A CN106038534 A CN 106038534A CN 201610493245 A CN201610493245 A CN 201610493245A CN 106038534 A CN106038534 A CN 106038534A
- Authority
- CN
- China
- Prior art keywords
- rubescensine
- depression
- medicine
- antidepressant
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 229940079593 drug Drugs 0.000 title abstract description 10
- SDHTXBWLVGWJFT-XKCURVIJSA-N oridonin Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12[C@@H](O)CCC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 SDHTXBWLVGWJFT-XKCURVIJSA-N 0.000 title abstract 5
- CAQAFLRZJHXSIS-UHFFFAOYSA-N oridonin Natural products CC1(C)C=CC(O)C23COC(O)(C(O)C12)C45C(O)C(CCC34)C(=C)C5=O CAQAFLRZJHXSIS-UHFFFAOYSA-N 0.000 title abstract 5
- 239000000725 suspension Substances 0.000 claims abstract description 11
- 230000037396 body weight Effects 0.000 claims abstract description 9
- 239000004615 ingredient Substances 0.000 claims abstract description 6
- 239000000935 antidepressant agent Substances 0.000 claims description 45
- 230000001430 anti-depressive effect Effects 0.000 claims description 28
- 229940005513 antidepressants Drugs 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 28
- 238000012360 testing method Methods 0.000 abstract description 23
- 229960004801 imipramine Drugs 0.000 abstract description 14
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 abstract description 14
- 241000581650 Ivesia Species 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 9
- 238000012048 forced swim test Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 229960002102 imipramine hydrochloride Drugs 0.000 description 4
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010054089 Depressive symptom Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241001646826 Isodon rubescens Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 244000292693 Poa annua Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- -1 diterpene compound Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015109224996 | 2015-12-14 | ||
CN201510922499 | 2015-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106038534A true CN106038534A (zh) | 2016-10-26 |
CN106038534B CN106038534B (zh) | 2019-08-16 |
Family
ID=57167278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610493245.1A Active CN106038534B (zh) | 2015-12-14 | 2016-06-28 | 冬凌草甲素在制备抗抑郁症药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106038534B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107157980A (zh) * | 2017-05-04 | 2017-09-15 | 武汉大学 | 冬凌草甲素在制备抗心肌重构药物中的用途 |
CN110151749A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学技术大学 | 冬凌草甲素在制备预防或治疗nlrp3炎症小体相关疾病的药物中的应用 |
CN113855665A (zh) * | 2021-09-28 | 2021-12-31 | 中山大学·深圳 | 冬凌草甲素和/或其前药在制备抑制SARS-CoV-2的药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104888122A (zh) * | 2015-06-12 | 2015-09-09 | 冀庆丽 | 一种治疗产后抑郁症的护理中药 |
-
2016
- 2016-06-28 CN CN201610493245.1A patent/CN106038534B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104888122A (zh) * | 2015-06-12 | 2015-09-09 | 冀庆丽 | 一种治疗产后抑郁症的护理中药 |
Non-Patent Citations (4)
Title |
---|
RAZ YIRMIYA 等: "Depression as a Microglial Disease", 《TRENDS IN NEUROSCIENCES》 * |
刘德祥: "氟西汀抑制脂多糖诱导的小胶质细胞炎症介质释放及其机制的研究", 《中国博士论文全文数据库》 * |
张典瑞 等: "冬凌草甲素固态类脂纳米粒在小鼠体内的组织分布及兔体内的药代动力学", 《药学学报》 * |
第3期: "Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107157980A (zh) * | 2017-05-04 | 2017-09-15 | 武汉大学 | 冬凌草甲素在制备抗心肌重构药物中的用途 |
CN107157980B (zh) * | 2017-05-04 | 2020-05-05 | 武汉大学 | 冬凌草甲素在制备抗心肌重构药物中的用途 |
CN110151749A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学技术大学 | 冬凌草甲素在制备预防或治疗nlrp3炎症小体相关疾病的药物中的应用 |
CN110151749B (zh) * | 2018-02-13 | 2022-04-19 | 中国科学技术大学 | 冬凌草甲素在制备预防或治疗nlrp3炎症小体相关疾病的药物中的应用 |
CN113855665A (zh) * | 2021-09-28 | 2021-12-31 | 中山大学·深圳 | 冬凌草甲素和/或其前药在制备抑制SARS-CoV-2的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106038534B (zh) | 2019-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105324114B (zh) | 虾青素抗炎增效组合 | |
JP6803898B2 (ja) | オメガ−3脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ | |
US20150065452A1 (en) | Anti-fatigue composition, formulation and use thereof | |
CN103432184B (zh) | 牛蒡子提取物在制药或食品中的应用 | |
CN106038534A (zh) | 冬凌草甲素在制备抗抑郁症药物中的用途 | |
CN103860530A (zh) | 虾青素作为抗抑郁症药物的用途 | |
CN103127163B (zh) | 一种缓解焦虑、抑郁,舒缓情绪、减轻精神压力的组合物及制备方法和用途 | |
CN106038522A (zh) | 大黄酸在制备抗抑郁症药物中的用途 | |
CO6180495A2 (es) | Formulacion de medicamento liquida | |
CN106265713B (zh) | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 | |
CN110446494A (zh) | 周围神经病变的治疗剂或预防剂 | |
CN114159447A (zh) | 18β-甘草次酸在制备治疗抑郁相关神经元保护药物中的应用 | |
CN107802621A (zh) | 青蒿素b抗神经炎症和治疗神经退行性疾病的用途 | |
CN103860578A (zh) | 香菇多糖作为抗抑郁症药物的用途 | |
CN105919991B (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
US2916417A (en) | Article of manufacture | |
CN111166774A (zh) | 一种具有防治脑缺血疾病的组合物及其应用 | |
CN114469967B (zh) | 一种苍术苷a及其衍生物在制备抗焦虑和抗抑郁药物上的应用 | |
CN108992463A (zh) | 一种治疗肺癌的组合物及药物制剂 | |
CN111228247B (zh) | 一种用于治疗包虫病的含苯亚甲基丙酮药物及其制备方法 | |
CN106821975A (zh) | 一种莫奈太尔口服液及其制备方法和应用 | |
CN110711198B (zh) | D-甘露糖在制备抗抑郁药物中的应用 | |
EP3466414B1 (en) | Use of nootkatone | |
CN112618524A (zh) | 一种改善睡眠障碍的asbdv组合物及其制剂与应用 | |
CN106474124B (zh) | 一种抑制菌丝和杀灭白念珠菌的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220602 Address after: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee after: Luo Yongqiang Address before: Room b273, Chuangxin building, No. 29, shengshengyuan Road, Changping District, Beijing 102206 Patentee before: BEIJING GRAGEN BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231206 Address after: Floor 3, Building 402, Zone 1, Tiantong Dongyuan, Dongxiaokou Town, Changping District, Beijing, 102218 Patentee after: Beijing Yasheng Bohou Biotechnology Development Center Address before: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee before: Luo Yongqiang |